GSE174159

Identifying new pronostic markers of IBD

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

34 case / 5 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Studying the variations in VNN1 expression at different stages of the disease and under therapy,

Overall design

A IBD biobank was generated starting with biopsy samples collected from patients suffering from CD or UC and diagnosed as clinically quiescent (Q) or in active phase of the disease (A). Patients were even not-treated at the period of diagnosis (NT) or responders or not to various therapies such as 5-ASA, anti-TNFalpha biologics (aTNF), corticoids (Cort) or immunosuppressors (IS). Controls were taken from non-inflammatory healthy portions of colon (CTRL). Transcriptome profiling was performed with RNA-Seq.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
39 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

2 linked publications 2 DOIs

Primary publication

  1. Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis. Gut, 2023

Related publications

  1. Shared Immune Associations Between COVID-19 and Inflammatory Bowel Disease: A Cross-Sectional Observational Study in Shanghai, China. Journal of inflammation research, 2024
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 6 samples need manual grouping review.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

6 review-needed samples and 0 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples were flagged for manual review.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Crohn's disease, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Treated 34 samples
  • Likely control group Mixed controls 5 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a treatment/control experiment. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 2 publications; 2 DOIs available: PMID 36175116, PMID 38558943.
  • Publication context: Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.. Gut, 2023. PMID 36175116. DOI 10.1136/gutjnl-2021-325792.
  • Publication context: Shared Immune Associations Between COVID-19 and Inflammatory Bowel Disease: A Cross-Sectional Observational Study in Shanghai, China.. Journal of inflammation research, 2024. PMID 38558943. DOI 10.2147/JIR.S449746.

Cautions

  • Downgraded for tissue search because it is a treatment/control experiment.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

173 fields

Sample Group Preview

39 rows shown
Show Hide
Study totals: Case 34 | Control 5 | Unassigned 0 | Excluded 0 | Ambiguous 0 39 rows shown
Group Role Accession Title Source / characteristics Reason
Treated Case GSM5288086 6_24_AM_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM5288087 9_23_Q_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288088 12_54_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288089 20_84_Q_IS Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Immunosuppressors (IS) Case marker detected.
Treated Case GSM5288090 7_91_AM_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM5288091 10_99_Q_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288092 13_54_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288093 17_3_Q_IS Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Immunosuppressors (IS) Case marker detected.
Treated Case GSM5288094 2_57_Q_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM5288095 11_100_Q_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288096 18_7_Q_IS Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Immunosuppressors (IS) Case marker detected.
Treated Case GSM5288097 1_28_Q_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM5288098 4_80_Q_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM5288099 5_82_AM_NT Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Non treated (NT) treated sample: Treated sample may need exclusion outside treatment comparisons.
Crohn's disease Case GSM5288100 15_94_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Ulcerative colitis Case GSM5288101 21_1_Q_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Quiescent (Q); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288102 26_49_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288103 27_49_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288104 35_68_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Ulcerative colitis Case GSM5288105 37_55_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Ulcerative colitis Case GSM5288106 39_93_AS_Cort Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Severe activity (AS); Treatment: Corticoids (Cort) Case marker detected.
Ulcerative colitis Case GSM5288107 40_44_AS_Cort Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Severe activity (AS); Treatment: Corticoids (Cort) Case marker detected.
Ulcerative colitis Case GSM5288108 41_96_AS_Cort Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Severe activity (AS); Treatment: Corticoids (Cort) Case marker detected.
Crohn's disease Case GSM5288110 8_47_Q_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Crohn's disease Case GSM5288111 19_83_Q_IS Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Crohn's disease (CD); Disease activity: Quiescent (Q); Treatment: Immunosuppressors (IS) Case marker detected.
Ulcerative colitis Case GSM5288112 22_1_Q_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Quiescent (Q); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288113 23_21_Q_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Quiescent (Q); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288114 24_22_Q_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Quiescent (Q); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288115 28_85_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288116 29_85_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288117 31_20_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288118 32_20_AM_5ASA Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: 5-ASA Case marker detected.
Ulcerative colitis Case GSM5288119 36_55_AM_TNF Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Moderate activity (AM); Treatment: Anti-TNFbiologics (TNF) Case marker detected.
Ulcerative colitis Case GSM5288120 38_90_AS_Cort Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Ulcerative colitis (UC); Disease activity: Severe activity (AS); Treatment: Corticoids (Cort) Case marker detected.
Control Control GSM5288109 46_50 Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Heathy control Sample-local control marker detected.
Healthy control Control GSM5288121 42_2 Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Healthy control; Disease activity: NA; Treatment: NA Sample-local control marker detected.
Healthy control Control GSM5288122 43_9 Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Healthy control; Disease activity: NA; Treatment: NA Sample-local control marker detected.
Healthy control Control GSM5288123 44_18 Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Healthy control; Disease activity: NA; Treatment: NA Sample-local control marker detected.
Healthy control Control GSM5288124 45_41 Intestinal biopsy Tissue: Intestinal biopsy; Disease state: Healthy control; Disease activity: NA; Treatment: NA Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.